Evidence map›Paper›PMID 28663891›Full record

ArticleBiomedical optics express2017

Pre-clinical longitudinal monitoring of hemodynamic response to anti-vascular chemotherapy by hybrid diffuse optics.

Parisa Farzam, Johannes Johansson, Miguel Mireles, Gabriela Jiménez-Valerio, Mar Martínez-Lozano, Regine Choe, Oriol Casanovas, Turgut Durduran

Abstract read
In one paragraph

Article in Biomedical optics express, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Parisa FarzamICFO-Institut de Ciències Fotòniques, The Barcelona Institute of Sciences and Technology, 08860, Castelldefels (Barcelona), Spain.
Johannes JohanssonICFO-Institut de Ciències Fotòniques, The Barcelona Institute of Sciences and Technology, 08860, Castelldefels (Barcelona), Spain.
Miguel MirelesICFO-Institut de Ciències Fotòniques, The Barcelona Institute of Sciences and Technology, 08860, Castelldefels (Barcelona), Spain.
Gabriela Jiménez-ValerioProgram Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology, Bellvitge Biomedical Research Institute - IDIBELL, 08908, L'Hospitalet de Llobregat (Barcelona), Spain.
Mar Martínez-LozanoProgram Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology, Bellvitge Biomedical Research Institute - IDIBELL, 08908, L'Hospitalet de Llobregat (Barcelona), Spain.
Regine ChoeDepartment of Biomedical Engineering, University of Rochester, Rochester, NY 14627, USA.
Oriol CasanovasProgram Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology, Bellvitge Biomedical Research Institute - IDIBELL, 08908, L'Hospitalet de Llobregat (Barcelona), Spain.
Turgut DurduranICFO-Institut de Ciències Fotòniques, The Barcelona Institute of Sciences and Technology, 08860, Castelldefels (Barcelona), Spain.

Funding

In Vivo Cancer Therapy Monitoring with Diffuse Optical MethodsR00CA126187 · NCI · UNIVERSITY OF ROCHESTER · PI CHOE, REGINE · 2011 to 2013
$710k
In Vivo Cancer Therapy Monitoring with Diffuse Optical MethodsK99CA126187 · NCI · UNIVERSITY OF PENNSYLVANIA · PI CHOE, REGINE · 2008 to 2009
$164k
NCI NIH HHS K99 CA126187NCI NIH HHS R00 CA126187
6 · The paper itself

Abstract

The longitudinal effect of an anti-vascular endothelial growth factor receptor 2 (VEGFR-2) antibody (DC 101) therapy on a xenografted renal cell carcinoma (RCC) mouse model was monitored using hybrid diffuse optics. Two groups of immunosuppressed male nude mice (seven treated, seven controls) were measured. Tumor microvascular blood flow, total hemoglobin concentration and blood oxygenation were investigated as potential biomarkers for the monitoring of the therapy effect twice a week and were related to the final treatment outcome. These hemodynamic biomarkers have shown a clear differentiation between two groups by day four. Moreover, we have observed that pre-treatment values and early changes in hemodynamics are highly correlated with the therapeutic outcome demonstrating the potential of diffuse optics to predict the therapy response at an early time point.

Indexed as

(110.4234) Multispectral and hyperspectral imaging(170.1470) Blood or tissue constituent monitoring(170.3660) Light propagation in tissues(170.3890) Medical optics instrumentation(170.6510) Spectroscopy, tissue diagnostics(300.6480) Spectroscopy, speckle

Identifiers

PMID28663891
PMCPMC5480498

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.